<DOC>
	<DOC>NCT00834301</DOC>
	<brief_summary>The purpose of the study is to determine whether an ingestion of a new renal multivitamin supplement can have a beneficial effect on bone and mineral adn inflammation issues related to patients on dialysis.</brief_summary>
	<brief_title>An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>End stage renal disease patients on dialysis for at least 90 days deemed to be at low risk by the investigator for being hospitalized or have concurrent infections Serum phosphorous level &gt; 5 mg/dl Stable phosphate binder regimen for 2 week prior to enrollment Stable dose of Vitamin D for 4 weeks prior to enrollment Stable calcimimetic dose for 4 week prior to enrollment patients who are pregnant patients who have pre existing thrombocytopenia defined as a platelet count of &lt;100 x 109/L abnormal LFTs baseline CRP &gt; 15 g/dl known sensitivity to any of the active ingredients patients who are currently enrolled in a clinical trial, or who have been in a clinical trial in the last six months are currently taking any immunosuppressive medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Inflammation</keyword>
</DOC>